Spruce Biosciences (SPRB) News Today $0.55 +0.02 (+3.79%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach OutNovember 1 at 5:32 PM | stockhouse.comSpruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation ConferenceOctober 28, 2024 | businesswire.comSpruce Biosciences (NASDAQ:SPRB) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comAnalysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Spruce Biosciences (SPRB)September 12, 2024 | markets.businessinsider.comThe Schall Law Firm Is Looking Into Whether Spruce Biosciences, Inc. Committed Securities Fraud And The Firm Wants Affected Shareholders To Reach OutSeptember 10, 2024 | stockhouse.comSpruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comThe Schall Law Firm Is Investigating Spruce Biosciences Inc For Potential Securities Law Violations And Investors Are Urged To Reach OutAugust 25, 2024 | stockhouse.comAn Securities Fraud Inquiry Has Been Opened Into Spruce Biosciences Inc And The Schall Law Firm Seeks Shareholder ParticipationAugust 24, 2024 | stockhouse.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)August 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spruce Biosciences Amid Anticipated Positive Clinical Trial Outcomes and Strong Financial PositionAugust 14, 2024 | markets.businessinsider.comSpruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesAugust 13, 2024 | finance.yahoo.comSPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024August 13, 2024 | investorplace.comOptimistic Outlook for Spruce Biosciences: Tildacerfont’s Market Potential Amidst Upcoming Trial DataJuly 26, 2024 | markets.businessinsider.comSpruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)June 4, 2024 | businesswire.comSpruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024June 3, 2024 | businesswire.comSpruce Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | finance.yahoo.comSpruce Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | businesswire.comHold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising CompetitionMay 16, 2024 | markets.businessinsider.comSpruce Biosciences, Inc. (SPRB)May 16, 2024 | finance.yahoo.comBuy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial PositionMay 15, 2024 | markets.businessinsider.comSPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | msn.comSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 13, 2024 | businesswire.comSpruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 30, 2024 | finance.yahoo.comSpruce Biosciences Inc (SPRB)April 26, 2024 | investing.comSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 22, 2024 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 27, 2024 | prnewswire.comRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)March 23, 2024 | finance.yahoo.comHoldings A/S Novo Sells 359,979 Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) StockMarch 22, 2024 | insidertrades.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 19, 2024 | prnewswire.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Major Shareholder Holdings A/S Novo Sells 1,912,316 SharesMarch 19, 2024 | insidertrades.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 16, 2024 | finance.yahoo.comSpruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs lowered shares of Spruce Biosciences from an "outperform" rating to a "market perform" rating in a report on Thursday.March 15, 2024 | marketbeat.comSpruce Biosciences Shares Dive 74% After Terminating Genetic Disease Study, Cutting StaffMarch 14, 2024 | marketwatch.comSpruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock FreefallMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 14, 2024 | businesswire.comStocks to Watch: Spruce Biosciences, UiPathMarch 14, 2024 | marketwatch.comSpruce Biosciences FY23 Loss Widens, CAHmelia-203 Study Fails; Stock Down In Pre-marketMarch 14, 2024 | markets.businessinsider.comWhy Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?March 14, 2024 | msn.comSpruce Biosciences (NASDAQ:SPRB) Downgraded by GuggenheimGuggenheim cut Spruce Biosciences from a "buy" rating to a "neutral" rating in a research report on Thursday.March 14, 2024 | marketbeat.comWhy Is Spruce Biosciences (SPRB) Stock Down 78% Today?March 14, 2024 | investorplace.comBuy Rating Affirmed for Spruce Biosciences Amid Clinical Trial Optimism and Advancing Dose CohortsMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences stock craters 75% on failed Phase 2 studyMarch 13, 2024 | msn.comSpruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial SetbacksMarch 13, 2024 | finance.yahoo.comTrading was temporarily halted for "SPRB" at 04:03 PM with a stated reason of "News pending."March 13, 2024 | marketbeat.comSpruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 13, 2024 | businesswire.comSpruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAHMarch 13, 2024 | businesswire.comSpruce Biosciences (SPRB) to Release Earnings on ThursdaySpruce Biosciences (NASDAQ:SPRB) will be releasing earnings on Thursday, March 14, Yahoo Finance reports.March 13, 2024 | marketbeat.comSpruce Biosciences' (SPRB) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $9.00 target price on shares of Spruce Biosciences in a research report on Tuesday.March 5, 2024 | marketbeat.comArmistice Capital LLC Cuts Stake in Spruce Biosciences, Inc. (NASDAQ:SPRB)Armistice Capital LLC trimmed its position in Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) by 12.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,056,000 shares of the company's stock after selling 442,000 shares during the pMarch 3, 2024 | marketbeat.com Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. SPRB Media Mentions By Week SPRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRB News Sentiment▼-0.320.43▲Average Medical News Sentiment SPRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRB Articles This Week▼21▲SPRB Articles Average Week Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BioAtla News Today I-Mab News Today Atlantic Coastal Acquisition Corp. II News Today PowerUp Acquisition News Today Oramed Pharmaceuticals News Today InflaRx News Today Oncolytics Biotech News Today Aileron Therapeutics News Today Kazia Therapeutics News Today Purple Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
